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Accumulating evidence indicates that oxidized low-density lipoprotein (OxLDL)is a useful marker for cardiovascular disease. The
uptake of OxLDL by scavenger receptors leads to the accumulation of cholesterol within the foam cells of atherosclerotic lesions.
OxLDL has many stimulatory eﬀects on vascular cells, and the presence of OxLDL in circulating blood has been established.
According to the classical hypothesis, OxLDL accumulates in the atherosclerotic lesions over a long duration, leading to advanced
lesions. However, recent studies on time-course changes of OxLDL in vivo raised a possibility that OxLDL can be transferred
between the lesions and the circulation. In this paper, the in vivo dynamics of OxLDL are discussed.
1.The Background ofOxLDLHypothesis
In the last three decades, a large volume of studies have
established that oxidized low-density lipoprotein(OxLDL)is
a useful marker for cardiovascular diseases (CVDs) (see [1–
6]).ThemeasurementofOxLDLcorrelateswiththepresence
of CVDs and indicates that OxLDL is a potential prognostic
marker for future health events. OxLDL is known to stimu-
late macrophages to induce foam cell formation and inﬂam-
matory responses. Although the pathological aspects of
OxLDL have been well studied, the formation, distribution,
and overall fate of OxLDL in vivo remain unclear.
The LDL receptor discovered by Goldstein and Brown
has central roles in the systemic and cellular metabolism of
cholesterol [7]. Cholesterol accumulates in atherosclerotic
lesions even in patients with familial hypercholesterolemia
having genetically impaired LDL receptor. This observation
raised the question of how lipid-laden foam cells are formed
withoutLDLreceptor. Theyalso suggestedtheimportance of
recognition of modiﬁed LDL by speciﬁc receptors. By using
acetylated LDL as the model ligand, they demonstrated the
presence of new receptors that facilitate foam cell formation,
whichwerecalledscavengerreceptors[8].Scavengerreceptor
type A (SR-A), the ﬁrst scavenger receptor to be identiﬁed,
is responsible for the recognition and uptake of acetylated
LDLand OxLDL[9, 10],butSR-Ais notthe sole receptorfor
modiﬁed LDL. More than 10 scavenger receptors have been
identiﬁed so far [11–13].
In 1984, Steinbrecher and his colleagues proposed that
oxidative modiﬁcation promotes foam cell formation from
macrophages and that the oxidativemodiﬁcation ofLDL can
beachievedthroughtheinteractionsofLDLwithendothelial
cells in vitro [14]. OxLDL induces a number of pro-
atherosclerotic eﬀects, including endothelial activation and
smooth muscle proliferation[14–19]. Berliner et al. reported
that the oxidative modiﬁcation of LDL through coculture
with endothelial cells had stimulatory eﬀects on many types
of cells and that these eﬀects are due to the oxidized
phospholipids generated in OxLDL [15]. The accumulation
of OxLDL in the foam cells in atherosclerotic lesions from
human coronary arteries, carotid arteries, and aortas of
Watanabe heritable hypercholesterolemic (WHHL) rabbits
has been demonstrated by immunohistochemical analysis
using anti-OxLDL monoclonal antibodies [20–23].
Since the clearance of OxLDL from the circulation is so
eﬃcient [24], OxLDL was believed initially to be absent in
blood. Anti-OxLDL monoclonal antibodies were applied to
sensitive ELISA procedures to measure very small amounts
of OxLDL in circulating blood [25–28]. Several research
groups, including ours, have demonstrated that the plasma
OxLDL level in patients with CVDs is signiﬁcantly higher
than the level measured in healthy subjects [21, 29–31].2 Journal of Lipids
The ELISA procedures introduced by these groups were dif-
ferent so that the values of the OxLDL measurements cannot
be directly compared; however, they all reported an increase
in OxLDL levels in patients with acute myocardial infarction
(AMI), cerebral infarction, or those receiving hemodialysis.
These observations strongly suggest that circulating OxLDL
is involved in atherosclerosis. The details of the ELISA
procedures used and the clinical observations have been
summarized previously [4].
It is still unclear how and when LDL is being oxidized. It
hasbeenlongbelievedthatLDLismodiﬁedinvesselwalland
subsequently accumulates in the tissue. However, Tsimikas
et al. showed that plasma OxLDL increases concomitant
with the regression of atheroscleroticlesions [32], suggesting
that OxLDL can be transferred between vessel wall and the
circulation.
Recently, the importance of the plasma OxLDL level as
a plausible predictive marker for secondary prevention has
been discussed [33–36]. To understand the role of OxLDL
in atherogenesis, it is important to clarify the behavior
of OxLDL in vivo during atherogenesis, particularly how
OxLDL is formed, how it moves around tissues, and how
it is metabolized. In this paper, we brieﬂy review recent
advances regarding dynamics and kinetics of OxLDL in vivo
and suggest several possibilities for future research.
2.TemporalChangesinPlasma OxLDLLevels
We and others started to measure human plasma OxLDL
levels using sandwich ELISA procedures [25–27]. The com-
bination of two antibodies, one for oxidized phosphatidyl-
cholines (OxPC) and the other for human apolipoprotein B
(apoB), enables accurate and eﬃcient detection of OxLDL;
a sl o wa s1n g / m Lo fO x L D Lc a nb em e a s u r e d .I nt h el a s t
15 years, many clinical studies were conducted using these
techniques. OxLDL levels increase in the plasma of patients
with several pathological conditions, including CVDs [21,
29, 30, 33], cerebral infarction [37], and hemodialysis for the
treatment of chronic renal failure [25, 28, 38]. This evidence
strongly suggests the involvement of in vivo OxLDL in
atherosclerosis and indicates that OxLDL levels may increase
in patients with symptoms of atherosclerosis. In addition,
recent studies demonstrated that temporal rises and falls in
plasma OxLDL levels occur under certain conditions.
Acute myocardial infarction (AMI) is caused by total
occlusion of a coronary artery following the rupture of
an atherosclerotic plaque and acute thrombosis. Ehara et
al. reported that the plasma OxLDL level in patients with
AMI increased by approximately 3.5 fold than in control
subjects [21]. However, this increase in the plasma OxLDL
level appeared to be a temporal change during followup
studies on the AMI patients. The increased plasma OxLDL
levels dropped to near the normal range by the time the
subjects were discharged from the hospital [33]. Similar
behavior of plasma OxLDL level was observed in patients
with cerebral infarction. The plasma OxLDL levels of these
patients increased for the ﬁrst few days following onset of
the disease, then returned to normal range within 30 days
60
50
40
30
20
10
0
S
u
r
f
a
c
e
l
e
s
i
o
n
a
r
e
a
(
%
)
0.01
0.02
0.03
0.04
0.05
0.06
P
l
a
s
m
a
O
x
L
D
L
l
e
v
e
l
(
n
g
/
μ
g
L
D
L
)
01 0 4 0 30 20
(weeks)
Lesion area
Plasma OxLDL
Figure 1: Temporal changes in plasma OxLDL levels and athero-
genesis in apoE-KO mice. Male apoE-KO mice were maintained
on normal diet up to 40 weeks. The atherosclerotic lesion on the
aortic surface increased sharply after 20 weeks. Plasma OxLDL
levels increased at 20 weeks just before the lesions began growing.
The plasma OxLDL levels seem to decrease concomitantly with an
increaseinthesizeofthelesion(citedfrom[41]withmodiﬁcation).
[37]. Similar temporal changes in plasma OxLDL levels
have been reported in patients with acute infarction of
the coronary arteries and after percutaneous transluminal
coronary angioplasty (PTCA) treatment [31, 39, 40]. AMI
is induced by spontaneous plaque rupture, and the plaque
can be further damaged by following PTCA treatment with a
balloon catheter and stent. Increased plasma OxLDL levels
after these acute events are partially due to the release of
OxLDL from the atherosclerotic plaques upon rupture [41].
The time-course behavior of OxLDL during the early
stages of atherogenesis was investigated. To utilize apolipo-
protein E knockout (apoE-KO) mice, a modiﬁed sandwich
ELISA procedure was used to determine the murine circulat-
ingOxLDLlevel[42].ApoE-KOmicedevelopatherosclerotic
lesions even when fed normal diet. The lesion area was
less than 1% of the whole aortic surface at 10 weeks, but
it gradually increased after 20 weeks, and it grew up to
32% by 40 weeks of age (Figure 1). The OxLDL level was
0.006ng/microgLDL at 6 weeks, but it was elevated to
0.042ng/microgLDLat20weeksandthendecreasedby60%
to 0.018ng/microgLDL at 28 weeks. This temporal rise in
OxLDL occurred before the size expansion of atherosclerotic
lesions in the aorta. This observation suggests that the
OxLDL is generated during atherogenesis in apoE-KO mice
in vivo. Reduction in the plasma OxLDL level coincided
with the increase in the development of the lesion and
accumulation of OxLDL in the atherosclerotic intima. One
possible explanation is that plasma OxLDL can transfer into
intimal lesions.Journal of Lipids 3
Tsimikas etal.studiedplasma OxLDLlevels(OxPC/apoB
ratios) during the regression of atherosclerosis in adult cy-
nomolgus monkeys and New Zealand white rabbits using
anti-OxPC and anti-apoB monoclonal antibodies [32]. They
showed that OxLDL levels correlated inversely with changes
in the size of lesions. Plasma OxLDL levels decreased during
theprogression oflesionsundera high-fat dietand increased
during the regression of these lesions after the diet was
changed to normal. This observation also suggests that
OxLDL can be transferred between the intimal regions and
the circulation.
Atherosclerotic lesions can regress under certain condi-
tions, such as a low-fat diet regimen or treatment with a
lipid-lowering drug. In human studies, increases in plasma
OxLDLlevelswasreportedinhealthyvolunteersfedalow-fat
diet [43]. After 37 healthy women took low-fat low-vegetable
diet for 5 weeks, OxPC/apoB ratio increased by 27%, while
total cholesterol did not change. In MIRACL study, patients
with unstable angina pectoris or AMI were treated with ator-
vastatin (80mg/day) for 16 weeks. Such treatment decreased
total cholesterol and total apoB but increased OxLDL levels
by 9.5% [44]. These observations suggest the possibility that
OxLDLcouldtranslocate betweenatheroscleroticlesions and
circulation. The rupture of a plaque could cause the rapid
releaseof OxLDLintothecirculation,butthismaynotbethe
onlywaytotransfer OxLDLfrom thelesionsinto circulation.
According to these recent studies, without tissue damage,
OxLDLmaypossiblybeequilibratedbetweentheplasma and
tissues (Figure 2).
In addition, trapping circulating OxLDL by injecting
anti-OxLDL antibodies or soluble form of the scavenger
receptor LOX-1 induced regression of atherosclerotic lesions
[45, 46]. Although that lipoprotein metabolism in rodents
m a yh a v es o m ed i ﬀerence from that of humans, it is nice if
the regression therapies of atherosclerosis become available.
3.The Siteof OxLDLFormation
One of the major issues regarding OxLDL is the site of
OxLDLformation in vivo.The most common way toprepare
OxLDL is to incubate isolated LDL fractions with micro-
molar concentrations of copper sulfate for 3–24 hours. The
copper ion induces lipid peroxidation chain reactions, and,
subsequently, the chemical modiﬁcation of the apoB protein
side chains with reactive lipid peroxidation products, such as
4-hydroxynonenal (4-HNE), acrolein, and malondialdehyde
(MDA). The presence of adducts of these oxidized products
onapoBproteinhasalsobeenimmunologicallyconﬁrmedin
atherosclerotic lesions [47–49]. Although concentrations of
metal ions are typically low in the plasma, including copper
ion, suﬃcient amounts of reducing compoundsand proteins
exist in the plasma that can protectLDLfrom oxidation[47].
However,whethercopperion-inducedLDLoxidationoccurs
under physiological conditions remains unclear [41].
Cell culture-dependent modiﬁcation of LDL has been
used to prepare “minimally modiﬁed LDL” (MM-LDL),
which is one form of oxidatively modiﬁed LDL [14, 15].
The chemical modiﬁcation of MM-LDL is moderate judg-
ing by increases in thiobarbituric acid-reactive substances
(TBARSs) and mobility in agarose gel electrophoresis, so
that MM-LDL binds to LDL receptor rather than scavenger
receptors. However, MM-LDL showed strong inﬂammatory
eﬀects on the cells in vessel wall tissues [15–17, 50]. MM-
LDL contains substantial amounts of OxPC, and OxPC
is believed to be partially responsible for these biological
eﬀects [51–53]. Sandwich ELISA system that uses the anti-
OxPC monoclonal antibody binds as competently to MM-
LDL as to copper-induced OxLDL [54]. Circulating OxLDL
may be qualitatively similar to MM-LDL, since OxLDL can
escape clearance system by the scavenger receptors and is
immunologically positive to measurement (Figure 3).
Heinecke et al. reported that chlorotyrosine and nitro-
tyrosine, which are generated by the myeloperoxidase-
(MPO-) dependent modiﬁcation of proteins, accumulate in
atheroscleroticlesions and in circulatingLDL [55,56]. MPO,
an enzyme that is secreted from macrophages and neu-
trophils, is involved in antibacterial host defense through
the generation of reactive oxygen species. MPO could
oxidize LDL particles, and the resulting OxLDL is taken
up by macrophages to form foam cells [57]. Since MPO
is able to modify LDL even in the presence of plasma in
vitro, MPO secreted by the macrophages and/or neutrophils
of atherosclerotic lesions could induce OxLDL formation.
According to this hypothesis, OxLDL is formed in inﬂam-
matory tissues rather than in the blood.
WenandLeakereportedaninterestingpossibilitytoform
OxLDL [58]. They incubated macrophages with aggregated
LDL to form foam cells. When the foam cells were cultured
for 7 days, 7-ketocholesterol and lipofuscin-like ﬂuorescent
materials were formed in the intracellular vesicles of the
foam cells. Since oxidative changes were inhibited by antiox-
idants and by the lysosomotropic agent chloroquine, they
proposed that LDL can be oxidized within the lysosomes of
macrophages.
We recently found the presence of OxLDL in human
gingival crevicular ﬂuid (GCF). Periodontitis, a major cause
of tooth loss in many countries, is a chronic infectious
disease that leads to the destruction of the connective tissue
attachmentsandalveolarbone.Recentstudieshavesuggested
that a correlation between atherosclerosis and periodontal
disease exists [59, 60]. GCF is a plasma exudate from
the microcirculation of gingival tissue, which is located in
the tiny space between the gingiva and tooth, and GCF
secretion increases in patients with periodontal disease [61].
GCF contains several plasma proteins, including cytokines,
hormones, and protectiveproteinstobacterial infection[62–
64], but the protein proﬁle of GCF is diﬀerent from that
of peripheral plasma. Using paper points, up to 1μLo f
GCF samples can be easily collected without damaging the
tissue, and the lipoprotein and cytokine concentrations can
be investigated. We found that LDL was present in GCF. In
addition, OxLDL was present in GCF samples collected from
healthy subjects. Surprisingly, the OxLDL level in the GCF
samples was 14-fold higher than in the plasma OxLDL levels
obtained from the same subjects [65]. The study on the GCF
from the periodontal lesions is ongoing. We demonstrated
that OxLDL induces IL-8 production in Ca9-22 human
gingival epithelial cells in culture, suggesting that OxLDL in4 Journal of Lipids
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Figure 2: Possible in vivo behavior of OxLDL. (a) The temporal rise and fall of plasma OxLDL levels suggest that MM-LDL (OxLDL) may
be transferred between the vessel wall tissues and circulation in the early stages of atherogenesis. In this stage, circulating OxLDL is likely
to be MM-LDL, since heavily oxidized LDL is very rapidly cleared from the circulation. The tissues of the vessel wall could be the site of
LDL oxidation, but further study is needed to examine whether oxidation proceeds in apparently healthy vessel walls during the very early
stages. When the plasma OxLDL level decreases atherosclerotic lesions appear to develop. (b) In advanced stages, many macrophages and
foam cells are found in the atherosclerotic lesions. MM-LDL could be further modiﬁed to form OxLDL in the lesions. OxLDL is taken up
by macrophages, and processed in the lysosomes.Some of the OxLDL is completely degraded, and a part of OxLDL is relatively resistant to
proteolytic processing. Partially degraded OxLDL particles are observed in the lesions. (c) Upon plaque rupture, or when an atherosclerotic
plaque is injured by PTCAtreatment, OxLDL andpartially degraded OxLDL are rapidly released from the lesionsinto the circulation, which
causes a temporal rise of the plasma OxLDL level.
GCF could function as an inﬂammatory stimulant [66]. If
OxLDL in GCF is simply transferred from circulation, the
ratio of OxLDL to LDL (same as OxLDL levels) should be
the same as that in plasma. These results suggest that the
OxLDL in GCF could be formed in periodontal pockets or
local gingival tissues rather than simply being transferred
from the plasma. It is an interesting view point that OxLDL
could be generated in extra-arterial tissues.
4.Th eP o s s i b l eF at eo fO x LD L
Scavengerreceptorsare a set ofreceptors thatbind toOxLDL
but not to native LDL particles. Macrophages and related
cells, such as Kupﬀer cells, express some of the scavenger
receptors, such as SR-A and CD36, but it is now apparent
that other types of cells such as endothelial cells also possess
other scavenger receptors [11–13]. Currently, scavenger
receptors are considered to be a set of pattern recognition
receptors that are expressed by the innate immune-defense
system against various pathogens [67, 68]. OxLDL and/or
the oxidized phospholipid components of OxLDL are also
recognized by Toll-like receptors 2 and 4 [69, 70], indicating
an overlap of the modiﬁcation structures on OxLDL and
nonself patterns recognized by defense system. Scavenger
receptors recognize OxLDL particles, because their modiﬁed
structuresaresimilar topathogen-related epitopesthereafter,
OxLDL is removed from the milieu by endocytosis. This
process is a part of self-defense responses, however, it may
cause accumulation of massive amount of lipids inside
macrophages.
In vivo evidence of OxLDL accumulation in foam cells
was obtained by immunohistochemical analysis [20–23].
Using an anti-OxPC monoclonal antibody, OxPC accumu-
lation was clearly observed in the cytoplasmic space offoam-
cell macrophages in the aortic lesions of WHHL rabbits
[20] and atherosclerotic lesions in human coronary arteriesJournal of Lipids 5
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Figure 3: Diﬀerence between OxLDL and MM-LDL. LDL is
thought to be modiﬁed in a stepwise manner during the generation
of OxLDL. In the initial phase of modiﬁcation, the lipid compo-
nents (sky blue circle) react with oxidation reagents, resulting in
radical chain reactions that produce many types of lipid oxidation
products (red, brown, yellow, or dark blue circle). Then, the lipid
oxidation products react with the apoB protein (blue line) to
generate adducts and cross-links. Radicals can attack the apoB
protein directly, resulting in oxidative changes of amino acid
side chains and the cleavage of peptide bonds (orange-grey line).
MM-LDL may contain lipid oxidation products without extensive
protein modiﬁcation, because it binds to LDL receptor rather than
scavenger receptors. As modiﬁcation on the apoB protein proceeds,
its mobility in the agarose gel electrophoresis changes greatly, andit
loses the aﬃnity to LDL receptor, and, in turn, it becomes a ligand
of scavenger receptors.
obtained from an autopsy specimen [21]. OxPC and apoB
strictly colocalized in the foamy macrophages of the lipid-
rich core of atherosclerotic lesions.
ApoBisa large proteinwith amolecularweight ofappro-
ximately 500kDa. During oxidative modiﬁcation, aggrega-
tion of LDL with conjugated apoB is formed. However,
partially degraded apoB fragments were found in atheroscle-
rotic lesions. On examining the LDL fraction extracted from
lesions of the human carotid artery by Western blotting with
anti-apoB monoclonal antibody, the size of apoB proteins in
the LDL extract was 100–200kDa [22]( Figure 2(b)). Partial
degradation of OxLDL in macrophages was observed using
macrophages in vitro, whereas acetylated LDL is completely
degradedin themacrophages[71, 72]. Cross-linking of apoB
protein formed in OxLDL may contribute to this resistance
to proteolysis. OxLDL is possibly processed by lysosomal
enzymes in foam cells. For future research, investigating
whether plasma OxLDL is partially degraded in patients
with AMI during the acute phase would be interesting.
Since the temporal rise and fall of plasma OxLDL levels
after plaque rupture are believed to be caused by release
from atherosclerotic lesions, such information would be an
important clue for elucidating the origin of OxLDL in the
circulation.
Another possibility that should be considered is whether
Lp(a) is a circulating OxLDL. A prospective clinical study
that examined the relationship between OxLDL and future
cardiovascular events showed a close overlap of plasma
OxLDL level and Lp(a) concentration [73]. The human LDL
fractions were further separated into subfractions by density,
and OxPC was found to be enriched with the subfractions
that contained Lp(a) [74]. Lp(a) is a unique LDL particle
in which apoB protein binds to another protein contain-
ing repeated kringle domains, apolipoprotein(a), through
a disulﬁde bond. Apolipoprotein(a) has some similarities
with plasminogen, but the physiological function of Lp(a) is
largely unknown.
The liver is the major organ responsible for OxLDL
metabolism. When radiolabeled OxLDL is injected into rats
via the femoral vain, most of the radioactivity is cleared
from circulation within 3 minutes, and more than 70% of
radioactivity goes to the liver [24]. OxLDL has been docu-
mented to accumulate in atherosclerotic lesions in the aorta
and coronary arteries of patients with CVDs; however, the
possible rolesandpathologicalchangesthatoccurin theliver
of patients with CVDs have not been studied in depth. The
proteolytic capabilities of liver cells may possibly be diﬀerent
from those of the macrophages in the vessel wall.
Kupﬀer cells, the macrophage-like cells of the liver, ex-
press scavenger receptors, including SR-A. However, it was
surprising that the clearance rate of OxLDL from circulation
in SR-A knockout mice was similar to that in normal mice
[75]. This suggests that there might be alternative receptors
or systems for the uptakeof OxLDL in liver cells. Recently, Li
etal.reportedthatbothKupﬀercellsandsinusoidalendothe-
lial cells in the liver endocytose OxLDL and MM-LDL, and
this process is mediated by the novel scavenger receptor
stabilin-2 [76]. Stabilins, speciﬁcally stabilin-1 and stabilin-
2, were initially found as receptors for hyarulonan [77, 78];
however, they were identical to FEEL-1 and FEEL-2, which
arereportedtobeendothelialscavengerreceptors[79].These
two stabilins are expressed in the sinusoidal endothelial cells
of the liver but show diﬀerent ligand speciﬁcities. Stabilin-1
binds to the both mildly and highly oxidized forms of LDL,
while stablin-2 selectively binds to the highly oxidized LDL.
When nonparenchymal cells, which contain both sinusoidal
endothelial cells and Kupﬀercells, were incubated with these
two forms of OxLDL, the uptake of mildly oxidized form
of LDL was observed only in endothelial cells, whereas both
cells were capable of taking up highly oxidized LDL. The co-
localization of OxLDL and stabilins has been demonstrated
byimmunoelectronmicrography. These observationssuggest
that endothelial cells might have a signiﬁcant role in
the metabolism of circulating modiﬁed LDL. If MM-LDL
represents the circulating form of OxLDL, endothelial cells
may be an important site of accumulation, metabolism, and
further modiﬁcation of MM-LDL (Figure 4).
Certain scavenger receptors, such as SR-A, CD36, and
LOX-1,havebeenextensively studiedtodeterminetheirrela-
tionship to foam cell formation and atherogenesis. However,
other receptors for OxLDL may possess diﬀerent tissue dis-
tributions and functions. Among scavenger receptors, SREC
and CL-P1 have been reported to be selectively expressed in6 Journal of Lipids
Sinusoidal EC
Kupffer cells
Stabilins
SR-A, etc.
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Figure 4: Stabilins, novel endothelial scavenger receptors, could
have a role in the clearance of OxLDL in the liver and from circu-
lation. Heavily oxidized LDL is taken up by Kupﬀer cells, whereas
sinusoidal endothelial cells can take up both mildly and highly
oxidized form of LDL. The novel scavenger receptors stabilin-1 and
-2,whichcanbindtobothtypes ofOxLDL,couldbe involvedinthe
process of clearing OxLDL from the circulation in the liver.
endothelial cells [80, 81], but the physiological functions of
these special receptors have not been clariﬁed. To elucidate
the clearance of OxLDL, studies on the contribution of
endothelial cells and the specialized receptors are required.
5.Conclusion
Recent studies have suggested the plasma OxLDL concentra-
tions may change under prepathological and postpatholog-
ical conditions. OxLDL may be transferred between tissues
and plasma and does not merely accumulate in the lesions
but is equilibrated between the tissues and circulation.
OxLDL can be formed in various sites in addition to the
tissue of the vessel wall. The liver is the major organ for the
clearance of OxLDL from circulation. However, many un-
knowns remain to be elucidated regarding the metabolic
fate of OxLDL in the liver. A recent study pointed out that
stabilins may have an important role in the recognition and
clearance of OxLDL and MM-LDL from circulation. The
receptors working in the liver may be diﬀerent from those
of cells in vessel wall tissues. Further studies are needed to
understand the in vivo behavior of OxLDL and elucidate
the contributions of OxLDL and oxidative stress to the
mechanism of atherogenesis.
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